AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.
Multiple Institutions Give AIM a "Buy" Rating HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA). The vaccine has demonstrated signific...
read full article
